Our Efforts to Develop a Vaccine and Identify Therapies for COVID-19

Scientific Progress Toward Treatment and Prevention Measures for COVID-19

A Vaccine Candidate
Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the fast-moving COVID-19 pandemic through the development of a possible preventive vaccine candidate against SARS-CoV-2.

  • Johnson & Johnson announced on March 30, 2020, that a lead COVID-19 vaccine candidate (with two back-ups) has been identified from constructs we have been working on since January 2020. We expect to begin Phase 1 clinical studies by September 2020 and anticipate the first batches of a COVID-19 vaccine to be available for emergency use in early 2021.
  • The Janssen Pharmaceutical Companies of Johnson & Johnson have entered into collaborations with Emergent BioSolutions, Inc. and Catalent Biologics to support the manufacturing of its lead investigational COVID-19 vaccine candidate. These are the first in a series of prospective global collaboration agreements designed to further the Company’s goal to supply more than one billion doses of the vaccine worldwide. Johnson & Johnson is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.
  • The COVID-19 vaccine program is leveraging Janssen’s AdVac® and PER.C6® technologies, that provide the ability to rapidly develop new vaccine candidates and upscale production of the optimal vaccine candidate, with demonstrated ability to manufacture millions of doses. These are the same technologies that were used in the development and manufacturing of our investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo and Rwanda, and were also used to construct the Company’s Zika, RSV and HIV vaccine candidates.

Treating COVID-19
Janssen is working with global partners to investigate pathways thought to play a role in coronavirus pathophysiology, and are screening a library of compounds for antiviral activity (including both ours and other companies’ compounds) in order to identify a solution that could contribute to providing immediate relief to the current pandemic. Janssen’s expanded partnership with BARDA includes seeking treatment solutions for those with COVID-19.

The Johnson & Johnson Response to COVID-19

Johnson & Johnson has a long-standing commitment to address global health crises and will continue to work closely with partners worldwide to combat the current COVID-19 pandemic through a multi-pronged approach.

Learn More About Our Efforts

More From Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.